Inventiva S.A. - IVA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 3.76% | 7,800,465 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 3.76% | 7,800,465 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Kroin | 3.76% | 7,800,465 | View |
| Apr 01, 2026 | SCHEDULE 13D/A | — | 5.0% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Great Point Partners, LLC | 3.49% | 6,783,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dr. Jeffrey R. Jay, M.D. | 3.49% | 6,783,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ms. Lillian Nordahl | 3.49% | 6,783,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Andera Partners | 7.7% | 14,114,476 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BioDiscovery 6 FPCI | 7.7% | 14,114,476 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Stephane Bergez | 7.7% | 14,114,476 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Francois Xavier Mauron | 7.7% | 14,114,476 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Sofinnova Crossover I SLP | 5.6% | 12,332,804 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Sofinnova Crossover II SLP | 3.1% | 6,753,246 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Sofinnova Partners SAS, a French corporation | 8.6% | 19,086,050 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Antoine Papiernik | 8.6% | 19,086,050 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Cedric Moreau | 8.6% | 19,086,050 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kinam Hong | 8.6% | 19,086,050 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Joseph Anderson | 8.6% | 19,086,050 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Jacques Theurillat | 5.6% | 12,332,804 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Eventide Asset Management, LLC | 4.6% | 9,368,517 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Finny Kuruvilla, M.D. Ph. D. | 4.6% | 9,368,517 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Robin C. John | 4.6% | 9,368,517 | View |
| Jan 30, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 6.07% | 11,668,983 | View |
| Jan 30, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 6.07% | 11,668,983 | View |
| Jan 30, 2026 | SCHEDULE 13G | David Kroin | 6.07% | 11,668,983 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.